Liquidia (NASDAQ:LQDA) Sees Strong Trading Volume – What’s Next?

Liquidia Corporation (NASDAQ:LQDA) saw an uptick in trading volume on Wednesday. Approximately 5,412,789 shares changed hands during trading, an increase of 217% from the previous session’s volume of 1,707,124 shares. The stock last traded at $39.0890 and had previously closed at $70.69.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Jefferies upgraded Liquidia to “strong buy,” potentially signaling confidence that YUTREPIA, the company’s underlying growth and its legal strategy retain significant value. Zacks Liquidia Stock News
• Positive Sentiment: Needham maintained a “buy” rating while lowering its price target from $110 to $72. The revised target still implies substantial potential upside from the approximately $28 share price, although it reflects greater litigation risk. Zacks Liquidia Stock News
• Neutral Sentiment: Liquidia plans to appeal the ruling and intends to seek removal of the PH-ILD indication from YUTREPIA’s label. The court has asked both companies to propose remedies within one week, so the ultimate commercial impact remains unresolved. Liquidia Hatch-Waxman Litigation Update
• Negative Sentiment: The ruling creates a major threat to YUTREPIA’s PH-ILD sales and could result in label restrictions, reduced market availability or an injunction sought by United Therapeutics. BTIG consequently downgraded LQDA to “neutral.” Seeking Alpha BTIG Downgrade
• Negative Sentiment: Investors reacted to the litigation setback with an exceptionally steep selloff, reflecting uncertainty over YUTREPIA’s principal growth opportunity despite recent revenue growth and profitability. An appeal could determine whether the shares recover. Yahoo Finance Liquidia Court Ruling

Analyst Ratings Changes

LQDA has been the subject of several analyst reports. Weiss Ratings upgraded Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Citigroup reissued a “neutral” rating on shares of Liquidia in a research note on Thursday. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research report on Sunday, September 20th. Jefferies Financial Group raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday. Finally, Wells Fargo & Company set a $30.00 price target on Liquidia in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $85.83.

Liquidia Trading Down 7.5%

The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of 20.43 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The firm has a fifty day moving average of $72.78 and a 200-day moving average of $62.26.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.Liquidia’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.49) EPS. As a group, equities analysts predict that Liquidia Corporation will post 2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, CAO Dana Boyle sold 1,600 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $87.53, for a total value of $140,048.00. Following the completion of the transaction, the chief accounting officer directly owned 167,919 shares of the company’s stock, valued at $14,697,950.07. This represents a 0.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Rajeev Saggar sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total value of $3,703,000.00. Following the sale, the insider owned 142,265 shares of the company’s stock, valued at $10,536,145.90. This represents a 26.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 597,519 shares of company stock worth $46,091,764. 25.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Liquidia

Hedge funds have recently bought and sold shares of the business. WINTON GROUP Ltd purchased a new stake in Liquidia during the 2nd quarter worth approximately $335,000. Arizona State Retirement System increased its stake in shares of Liquidia by 5.4% in the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after buying an additional 900 shares during the last quarter. Nykredit A S acquired a new stake in Liquidia in the second quarter valued at $177,000. Corient Private Wealth LP acquired a new stake in Liquidia in the second quarter valued at $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Liquidia during the 2nd quarter valued at $1,236,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).